Steroid administration for post‐COVID‐19 Parkinsonism: A case report

A 45‐year‐old man developed parkinsonism 3 weeks after being diagnosed with mild COVID‐19. Levodopa and benserazide failed to improve his symptoms, necessitating ropinirole, and steroid treatment, which included a 5‐day course of methylprednisolone followed by a 3‐month oral prednisolone taper. One...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neurology and clinical neuroscience 2023-01, Vol.11 (1), p.49-51
Hauptverfasser:	Mitarnun, Witoon, Apiwattanakul, Metha, Thodthasri, Thanatchanan, Tantisungvarakoon, Praewa, Pangwong, Wilasinee
Format:	Artikel
Sprache:	eng
Schlagworte:	antiparkinsonian medication Basal ganglia Brain diseases Case Report Case Reports Central nervous system diseases COVID-19 Levodopa Methylprednisolone Movement disorders Parkinsonism Prednisolone severe acute respiratory syndrome coronavirus 2 steroids
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A 45‐year‐old man developed parkinsonism 3 weeks after being diagnosed with mild COVID‐19. Levodopa and benserazide failed to improve his symptoms, necessitating ropinirole, and steroid treatment, which included a 5‐day course of methylprednisolone followed by a 3‐month oral prednisolone taper. One month after initiating steroid treatment, his symptoms improved significantly.
ISSN:	2049-4173 2049-4173
DOI:	10.1111/ncn3.12679